Michael Ehlers

Michael Ehlers
Born
NationalityAmerican
Alma materCaltech, Johns Hopkins University
Known forneurotransmitter receptors
Scientific career
FieldsNeuroscience
InstitutionsBiogen
Doctoral advisorRichard L. Huganir

Michael D. Ehlers is Chief Scientific Officer and a venture partner at life sciences venture capital firm Apple Tree Partners. He was formerly Executive Vice President for Research and Development at Biogen and before that was Chief Scientific Officer for Neuroscience at Pfizer. Prior to joining industry, Ehlers was the George Barth Geller Professor of Neurobiology and a Howard Hughes Medical Institute investigator at the Duke University Medical Center. His academic work was focused around neuronal organelles and the trafficking of neurotransmitter receptors.[1]

He has a BS in chemistry from Caltech in 1991 and an MD and a PhD in neuroscience at Johns Hopkins School of Medicine with Richard L. Huganir.[2] His work at Duke was centered around the trafficking of neurotransmitter receptors notably the AMPA receptor.[3][4]

Ehler was born in Germany and raised in rural Nebraska. He plays French horn and piano. He first became interested in science as a child collecting insects and rocks. He was introduced to neurobiology when his girlfriend now wife suggested that math was involved with the field.[5]

References

[edit]
  1. ^ "Michael Ehlers". Neuron. 91 (1): 15–18. July 2016. doi:10.1016/j.neuron.2016.06.024.
  2. ^ "Angelman Syndrome Foundation". www.angelman.org. Retrieved 12 March 2018.
  3. ^ Ehlers, Michael D (November 2000). "Reinsertion or Degradation of AMPA Receptors Determined by Activity-Dependent Endocytic Sorting". Neuron. 28 (2): 511–525. doi:10.1016/S0896-6273(00)00129-X. PMID 11144360. S2CID 16333109.
  4. ^ Park, M. (24 September 2004). "Recycling Endosomes Supply AMPA Receptors for LTP". Science. 305 (5692): 1972–1975. Bibcode:2004Sci...305.1972P. doi:10.1126/science.1102026. PMID 15448273. S2CID 34651431.
  5. ^ "Interview with Michael D. Ehlers". Trends in Neurosciences. 35 (5): 271–273. May 2012. doi:10.1016/j.tins.2011.12.008. S2CID 53201895.